Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

M. J. Lechowicz; H. M. Lazarus; J. Carreras; G. G. Laport; C. S. Cutler; P. H. Wiernik; G. A. Hale; D. Maharaj; R. P. Gale; P. A. Rowlings; C. O. Freytes; A. M. Miller; J. M. Vose; R. T. Maziarz; S. Montoto; D. G. Maloney; P. N. Hari

doi:10.1038/bmt.2014.161

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

M. J. Lechowicz, H. M. Lazarus, J. Carreras, G. G. Laport, C. S. Cutler, P. H. Wiernik, G. A. Hale, D. Maharaj, R. P. Gale, P. A. Rowlings, C. O. Freytes, A. M. Miller, J. M. Vose, R. T. Maziarz, S. Montoto, D. G. Maloney, P. N. Hari

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Abstract

We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

Original language	English (US)
Pages (from-to)	1360-1365
Number of pages	6
Journal	Bone marrow transplantation
Volume	49
Issue number	11
DOIs	https://doi.org/10.1038/bmt.2014.161
State	Published - Nov 13 2014

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/bmt.2014.161

Cite this

Lechowicz, M. J., Lazarus, H. M., Carreras, J., Laport, G. G., Cutler, C. S., Wiernik, P. H., Hale, G. A., Maharaj, D., Gale, R. P., Rowlings, P. A., Freytes, C. O., Miller, A. M., Vose, J. M., Maziarz, R. T., Montoto, S., Maloney, D. G., & Hari, P. N. (2014). Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone marrow transplantation, 49(11), 1360-1365. https://doi.org/10.1038/bmt.2014.161

Lechowicz, MJ, Lazarus, HM, Carreras, J, Laport, GG, Cutler, CS, Wiernik, PH, Hale, GA, Maharaj, D, Gale, RP, Rowlings, PA, Freytes, CO, Miller, AM, Vose, JM, Maziarz, RT, Montoto, S, Maloney, DG & Hari, PN 2014, 'Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome', Bone marrow transplantation, vol. 49, no. 11, pp. 1360-1365. https://doi.org/10.1038/bmt.2014.161

@article{ea8ee3ed2c64462bb5c87273cd18790d,

title = "Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome",

abstract = "We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.",

author = "Lechowicz, {M. J.} and Lazarus, {H. M.} and J. Carreras and Laport, {G. G.} and Cutler, {C. S.} and Wiernik, {P. H.} and Hale, {G. A.} and D. Maharaj and Gale, {R. P.} and Rowlings, {P. A.} and Freytes, {C. O.} and Miller, {A. M.} and Vose, {J. M.} and Maziarz, {R. T.} and S. Montoto and Maloney, {D. G.} and Hari, {P. N.}",

note = "Publisher Copyright: {\textcopyright} 2014 Macmillan Publishers Limited.",

year = "2014",

month = nov,

day = "13",

doi = "10.1038/bmt.2014.161",

language = "English (US)",

volume = "49",

pages = "1360--1365",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

AU - Lechowicz, M. J.

AU - Lazarus, H. M.

AU - Carreras, J.

AU - Laport, G. G.

AU - Cutler, C. S.

AU - Wiernik, P. H.

AU - Hale, G. A.

AU - Maharaj, D.

AU - Gale, R. P.

AU - Rowlings, P. A.

AU - Freytes, C. O.

AU - Miller, A. M.

AU - Vose, J. M.

AU - Maziarz, R. T.

AU - Montoto, S.

AU - Maloney, D. G.

AU - Hari, P. N.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

AB - We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

UR - http://www.scopus.com/inward/record.url?scp=84909982000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909982000&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.161

DO - 10.1038/bmt.2014.161

M3 - Article

C2 - 25068422

AN - SCOPUS:84909982000

SN - 0268-3369

VL - 49

SP - 1360

EP - 1365

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 11

ER -

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this